The Australian Pharmaceutical Biostatistics Group are excited to announce our AGM and End of Year meeting will be held on 8th December at The Macquarie Business School CBD Campus, level 24/123 Pitt St, Sydney from 2.15pm – 5.00pm as well as online.

Following the formal AGM, Michael Fitzgerald, Director of Biostatistics at Phastar will give an in-person presentation on Missing Data and Multiple Imputation, sharing insights and strategies through a case study with a recurrent event endpoint. Please RSVP to apbgsteering@gmail.com for catering purposes and to receive the meeting link.

Date/Time
8th December, 2.15-5.00pm

Location
The Macquarie Business School CBD Campus, level 24/123 Pitt St, Sydney, and online

Agenda
2.15pm Arrival tea and coffee
2.30pm AGM including vote on new constitution
3.30pm Afternoon tea
4.00pm Michael Fitzgerald – Missing Data and Multiple Imputation
5.00pm Meeting close
5.45pm Dinner - optional, details to be provided later

Missing Data and Multiple Imputation

Speaker: Michael Fitzgerald, Director of Biostatistics, Phastar

Abstract: This presentation will share a case using simulated data based on a real study where the primary endpoint was recurrent event data. We will describe the missing data strategy for the primary analysis and sensitivity analyses that were planned, plus a bonus method using multiple imputation and pattern mixture models for a tipping-point analysis which we recommend is used for future studies.

Biography: 

Michael Fitzgerald is a Director of Statistics at Phastar, primarily working in clinical trials across a diverse range of therapeutic areas with pharma, biotech, and MedTech, while building a team of statisticians for Phastar across the Asia-Pacific region. Michael learned his trade as a statistician working on investigator-led studies while working at the University of Newcastle’s Centre for Clinical Epidemiology & Biostatistics and in the Hunter Medical Research Institute.

Michael has been honing his skills in the application of advanced missing data techniques over the past 12 years while working on late-phase trials, this has become particularly important with the rise of the estimands framework and expectations of more robust sensitivity analysis from regulators and sponsors.